WO2013186418A1 - Marqueur moléculaire de puissance thérapeutique de cellules mères mésenchymales humaines et ses utilisations - Google Patents

Marqueur moléculaire de puissance thérapeutique de cellules mères mésenchymales humaines et ses utilisations Download PDF

Info

Publication number
WO2013186418A1
WO2013186418A1 PCT/ES2013/070381 ES2013070381W WO2013186418A1 WO 2013186418 A1 WO2013186418 A1 WO 2013186418A1 ES 2013070381 W ES2013070381 W ES 2013070381W WO 2013186418 A1 WO2013186418 A1 WO 2013186418A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
mir
cells
expression
activity
Prior art date
Application number
PCT/ES2013/070381
Other languages
English (en)
Spanish (es)
Other versions
WO2013186418A9 (fr
Inventor
Manuel Angel GONZÁLEZ DE LA PEÑA
Antonio Bernad Miana
María TOMÉ PIZARRO
Original Assignee
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii filed Critical Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii
Publication of WO2013186418A1 publication Critical patent/WO2013186418A1/fr
Publication of WO2013186418A9 publication Critical patent/WO2013186418A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the present invention falls within the field of molecular biology and biomedicine. Specifically, the present invention relates to the use of miR-335 as a molecular marker to quantify the therapeutic potency of human mesenchymal stem cells employed in regenerative medicine.
  • MSC Mesenchymal stem cells
  • hMSC Human mesenchymal stem cells
  • MSCs have a great therapeutic potential in tissue regeneration, since isolated and expanded MSCs in culture are able to differentiate into osteoblasts, chondrocytes, myocytes and adipocytes, among other cell types, and can be subsequently reintroduced into the human body to Repair lost or damaged tissues.
  • Another characteristic that is even more valuable in clinical practice is its immunomodulation capacity, which makes them extremely useful for the treatment of immune-based diseases.
  • very little is still known about the mechanisms that regulate its biological and therapeutic properties.
  • the MSCs used for cell therapy are considered medications, so their use must comply with the Drug Law, be handled according to GMP, etc.
  • a therapeutic entity that is going to be used as a medicine must go through sterility controls (eg, mycoplasma free), identity (markers), purity (contaminants), and potency.
  • the release of lots of MSC for clinical use should be in less than 24 hours because if the cells do not die or deteriorate, so no power control is currently performed because all known methods take weeks for each batch.
  • MSCs have great variability in their therapeutic potential. At present, this potential cannot be known a priori (expensive and time-delayed studies are necessary), so many samples that are really suboptimal can be stored, with the consequent expense and possible harm to patients. There is therefore a need to develop a method that allows to quickly and efficiently determine the therapeutic potential of the MSC batches in order to determine their suitability for administration to a patient.
  • hMSC human mesenchymal stem cells
  • the present invention relates to a method for determining the immunoregulatory capacity or potency of a stem cell, which comprises determining in said stem cell the levels of expression and / or activity of miR-335, where levels high with respect to a reference value are indicative that said stem cell has a low immunoregulatory capacity, or where decreased levels with respect to a reference value are indicative that said stem cell has a high immunoregulatory capacity.
  • the invention in another aspect, relates to a method for selecting a batch of stem cells for therapeutic applications related to the immunoregulatory activity of said stem cells which comprises determining in the stem cells of said batch the miR expression levels and / or activity -335, where if the expression and / or activity levels of miR-335 are lower than a reference value, the batch of stem cells is selected for therapeutic applications related to the immunoregulatory activity of said stem cells.
  • the invention in another aspect, relates to a method for selecting a batch of stem cells for therapeutic applications related to the immunoregulatory activity of said stem cells comprising determining the levels of expression and / or activity of miR335 in stem cells of said batch and in the stem cells of a control lot previously selected as suitable for therapeutic applications related to immunoregulatory activity, where if the levels of expression and / or activity of miR335 in the stem cells are similar to the levels of expression and / or activity of miR335 in the cells of the control lot, then the batch of stem cells is selected for therapeutic applications related to the immunoregulatory activity of said stem cells.
  • the invention relates to a kit for determining the immunoregulatory capacity of a stem cell comprising
  • the invention in another aspect, relates to an in vitro method for increasing the immunoregulatory capacity of a stem cell, which comprises inhibiting the expression and / or activity of miR-335 in said stem cell.
  • the invention relates to a use of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 to prepare a medicament for the treatment of a disease selected from the group formed by an autoimmune disease, a inflammatory disease, graft versus host disease, type 1 diabetes, type 2 diabetes and cardiovascular disease.
  • the invention relates to a use of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 to prepare a medicament for inducing tolerance to a transplant.
  • the invention relates to a use of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 to prepare a medicament for tissue repair and regeneration.
  • the invention in another aspect, relates to an in vitro method for generating regulatory T cells, which comprises contacting a population of cells containing T cells with a population of stem cells characterized in that they have reduced levels of expression and / or activity of miR-335 under conditions suitable for the generation of regulatory T cells.
  • FIG. 1 Expression levels of miR-335 in hMSC are directly related to the age of the donor. Relative expression of miR-335 (using the expression of RNU6B as an endogenous control) measured by quantitative real-time RT-PCR in different types of hMSC from different donors. A) Expression level of miR-335 measured in hMSC from bone marrow. B) Level of expression of miR-335 measured in hMSC from adipose tissue.
  • FIG. 1 Cellular senescence levels in hMSC cultures are directly related to miR-335 expression levels.
  • FIG. 3 The expression level of miR-335 is inversely related to telomeric length in hMSC.
  • FIG. 4 Relationship between the endogenous levels of miR-335 and the partial pressure of O2 during culture.
  • HMSC of adipose tissue from three different donors Ad 36, Ad 40 and Ad 43 were grown at 3% (white bars) or 20% (black bars) of 0 2 for one week.
  • Endogenous levels of miR-335 were measured by quantitative real-time PCR.
  • FIG. 5 Overexpression of miR-335 decreases the in vitro immunoregulatory capacity of hMSCs.
  • Human peripheral blood mononuclear cells (PBMC) were stimulated with SEB (Ing / mL), in the absence or presence of an increasing number of hMSC, which were transduced with the lentiviral construct pLV-EmGFP-MIR335 or pLV-EmGFP- mock The antiproliferative response was determined at 96 hours of culture by measuring the incorporation of BrdU into the PBMC.
  • FIG. 6 Overexpression of miR-335 decreases the in vivo immunoregulatory capacity of hMSCs. Death by endotoxemia was induced in a murine model (BALBc mice) by intraperitoneal (ip) injection of 400 ⁇ g of LPS. Half an hour after the administration of LPS, bone marrow hMSC was administered in order to avoid such death by endotoxemia.
  • mice were used for each of the following experimental groups: negative control (LPS 400 ⁇ g + PBS), unmodified hMSC (LPS 400 ⁇ g + bm-hMSC 19 wt), hMSC transduced with a lentiviral control vector, which encodes a miRNA without targets in the human genome (LPS 400 ⁇ g + bm-hMSC 19 mock), and hMSC transduced with a lentiviral vector encoding miR-335 ( LPS 400 ⁇ g + bm-hMSC 19 335).
  • the figure shows the survival curve of the animals of each experimental group during the 96 h after administration of the LPS.
  • the present invention is based on the discovery that miR-335 expression levels are inversely related to the immunomodulatory activity of hMSC, that is, that elevated miR-335 levels result in cells that have a lower immunomodulatory capacity and that , so levels Reduced miR-335 results in cells that have a greater immunomodulatory capacity. Since the therapeutic activity of hMSCs depends mainly on their immunomodulatory / anti-inflammatory activity, the present inventors propose that the expression levels of said miR-335 are predictive of the therapeutic potency of said cells, in particular their immunoregulatory capacity.
  • the present invention relates to a method, hereinafter the first method of the invention, for determining the immunoregulatory capacity or potency of a stem cell, which comprises determining in said stem cell the levels of expression and / or activity of miR-335, where high levels with respect to a reference value are indicative that said stem cell has a low potency or immunoregulatory capacity, or where decreased levels with respect to a reference value are indicative that said stem cell has a high power or immunoregulatory capacity.
  • stem cell refers to a totipotent, pluripotent or multipotent cell, capable of generating one or more differentiated cell types, and which also has the ability to regenerate itself, ie , to produce more stem cells.
  • Totipotent stem cells can give rise to both the embryonic components (such as the three embryonic layers, the germ lineage and the tissues that will give rise to the yolk sac), as well as to the extraembryonic (like the placenta). That is, they can form all cell types and give rise to a complete organism.
  • Pluripotent stem cells can form any type of cell corresponding to the three embryonic lineages (endoderm, ectoderm and mesoderm), as well as the germinal and yolk sac.
  • Multipotent stem cells are those that can only generate cells of the same embryonic layer or lineage of origin.
  • the stem cell is not a human embryonic stem cell.
  • the stem cell of the first method of the invention is an adult stem cell.
  • adult stem cell means that the stem cell is isolated from a tissue or organ of an animal in a state of growth after the embryonic state.
  • the stem cells of the invention have been isolated in a postnatal state.
  • they have been isolated from a mammal, and more preferably from a human, including neonates, juveniles, adolescents and adults.
  • Adult stem cells can be assimilated from a wide variety of tissues and organs, such as bone marrow (mesenchymal stem cells, multipotent adult progenitor cells and hematopoietic stem cells), adipose tissue, cartilage, epidermis, hair follicle, skeletal muscle, heart muscle, intestine , liver, neuronal, etc.
  • the stem cell of the first method of the invention is a mesenchymal stem cell.
  • MSC meenchymal stem cell
  • mesoderm a multipotent somatic stem cell derived from mesoderm, which has the ability to regenerate itself and to differentiate itself to produce descendant cells with a wide phenotypic variety, including connective tissues, bone marrow stroma, adipocytes, dermis and muscle, among others.
  • MSCs have an expression profile of cellular markers characterized in that they are negative for markers CD19, CD45, CD14 and HLA-DR, and are positive for markers CD105, CD106, CD90 and CD73.
  • the MSCs originate from bone marrow or subcutaneous adipose tissue.
  • Bone marrow MSCs can be isolated by procedures known to those skilled in the art. In general, these methods consist of isolating Mononuclear cells by density gradient centrifugation (Ficoll, Percoll) of bone marrow aspirates, and subsequently sow isolated cells in tissue culture plates in medium containing bovine fetal serum. These methods are based on the ability of MSCs to adhere to plastic, so that while non-adherent cells are removed from the culture, adhered MSCs can expand into culture plates. MSCs can also be isolated from subcutaneous adipose tissue following a similar procedure, known to the person skilled in the art. A method for isolating MSC from bone marrow or subcutaneous adipose tissue has been previously described (De la Fuente et al, Exp. Cell Res. 2004, Vol. 297: 313: 328).
  • the first method of the invention allows to determine the immunoregulatory power or capacity of a stem cell.
  • Immunoregulatory capacity or potency means the property that stem cells have to suppress the immune response by inhibiting the maturation of dendritic cells and suppressing the function of T and B lymphocytes and Natural Killer cells in autoimmune diseases. and inflammatory.
  • the immunoregulatory capacity or potency of the stem cells of the first method of the invention can be analyzed in vitro by a lymphocyte proliferation inhibition assay (Example 3.1.).
  • the immunoregulatory capacity of said cells can also be analyzed in vivo by an endotoxemia induction assay by intraperitoneal injection of LPS (Example 3.2.).
  • a stem cell with a greater capacity or immunoregulatory power also has a greater therapeutic potential, both when used for the treatment of diseases in which there is an unwanted activity of the immune system (autoimmune or inflammatory diseases), since they have a greater therapeutic effect, as for the treatment of diseases that require tissue repair (since tissue repair has an inflammatory component and a greater immunosuppressive capacity allows to prevent the host from rejecting the cells when they are of allogeneic or xenogenic origin).
  • the therapeutic potential of a stem cell is the result of a set of properties of said cell, such as its proliferation and migration capacity, its differentiation potential and its immunoregulatory capacity.
  • the proliferation and migration capacity and the differentiation potential of a stem cell correlate negatively with the senescence of said stem cell.
  • stem cells that have reduced expression levels of miR-335 have a greater immunoregulatory capacity, a lower senescence and a greater therapeutic potency.
  • microRNA is a single-stranded RNA, between 21 and 25 nucleotides in length, which has the ability to regulate the expression of other genes through various processes, using the path of ribointerference. MicroRNAs post-translationally regulate gene expression by repressing the translation of a target messenger RNA.
  • a microRNA is complementary to a region of one or more messenger RNAs (mRNAs).
  • miR-335" refers to the human microRNA as defined in the microRNA base "miRBase: Sequences” of the Wellcome Trust Sanger Institute (http: //microrna.sanger .ac.uk / sequences / index.shtml).
  • miR-335 maps on the human chromosome 7q32.2 and is located within the second intron of the MEST / PEG1 gene that is one of the few human coding genes that have a maternal imprint. The expression of miR-335 therefore depends on the expression of MEST / PEG1.
  • miR-335 includes both the premature form thereof, mir-335 ⁇ Accession number MI0000816, and the mature forms miR-335-5p ⁇ Accession number MIMAT0000765) and miR-335-5p ⁇ Accession number MIMAT0004703), as defined in the "miRBase: Sequences" database of the Wellcome Trust Sanger Institute (http://microrna.sanger.ac.uk/sequences/index.shtml), Relay 18 (November 2011 ).
  • the first method of the invention involves, in a first step, determining in a stem cell or stem cell population the levels of expression and / or activity of miR-335.
  • RNA can be purified from the stem cells by homogenization in the presence of a nucleic acid extraction buffer, followed by centrifugation. Acids Nuclei are precipitated and the DNA is removed by DNase treatment and precipitation. Nucleic acids, specifically RNA and specifically miRNA, can be isolated by any technique known to those skilled in the art. There are two main methods to isolate RNA: (i) phenol-based extraction and (ii) silica matrix or glass fiber filter (GFF) binding.
  • GFF silica matrix or glass fiber filter
  • Phenol-based reagents contain a combination of denaturing and RNAse inhibitors for the breakdown of cells and tissues and the subsequent separation of RNA from contaminants. Phenol-based isolation procedures can recover RNA species in the range of 10-200 nucleotides for example, miRNA, ribosomal RNA (rRNA) and small nuclear RNA (RNAs). If a sample of total RNA was purified by the GFF procedure or conventional silica matrix column, small-sized RNAs may have been lost. However, extraction procedures such as those using Trizol or TriReagent will purify all RNAs, large and small, and are the recommended methods to isolate total RNA from biological samples that will contain miRNA. Any method required for the treatment of a sample before quantification of the expression level of miR-335 is within the scope of the present invention.
  • RNA preparation of the stem cells to be analyzed requires determining the levels of miR-335 expression in the RNA isolated from stem cells.
  • Methods for determining microRNA expression levels in cells or biological samples include generic methods for the detection and quantification of nucleic acids, especially RNA, optimized methods for the detection and quantification of small RNA species, since both mature microRNAs and precursors fall within this category, as well as methods specially designed for the detection and quantification of microRNA.
  • Illustrative, non-limiting examples of methods that can be employed to determine the levels of one or more microRNAs include:
  • Methods based on hybridization such as Northern blot analysis and in situ hybridization.
  • RT-PCR Real-time multiplex and / or singleplex RT-PCR (reagents available from, for example, Applied Biosystems and System Biosciences (SBI)), including PCR with Quantitative real-time reverse transcriptase (qRT-PCR) as described in US 5,928,907 and US 6,015,674;
  • the expression level of miR-335 is determined by real-time quantitative RT-PCR (qRT-PCR), a modification of the polymerase chain reaction (PCR) used to rapidly measure the amount of a PCR product.
  • qRT-PCR real-time quantitative RT-PCR
  • PCR polymerase chain reaction
  • This is preferably done in real time, therefore it is an indirect method to quantitatively measure starting quantities of DNA, complementary DNA or RNA. This is commonly used to determine if a genetic sequence is present or not, and if the number of copies in the sample is present.
  • the procedure is based on the amplification of DNA samples, using thermal cycles and a thermostable DNA polymerase.
  • the three commonly used quantitative PCR methods are: by agarose gel electrophoresis, by using SYBR Green (a double stranded DNA dye) and by a fluorescent indicator probe. The last two methods can be analyzed in real time, thus constituting real-time PCR methods.
  • the fluorescent indicator probe method is the most accurate and the most reliable of the methods. It uses a sequence-specific nucleic acid-based probe, so that it only quantifies the sequence that hybridizes with the probe and not all double stranded DNA. Said probe, which has at its 3 'end a fluorophore and at its 5' end a molecule that blocks its flourescence emission (quencher or quencher), hybridizes specifically in the central part of the PCR product to be obtained.
  • the probe when PCR is performed with the probe plus the pair of specific primers, the probe amplicon hybrid but, due to the proximity of the fluorophore to the damper, flourescence is not emitted; when the polymerase begins to synthesize the complementary chain for the single-stranded template DNA primed, as the polymerization progresses, it reaches the probe attached to its complementary sequence, so that the polymerase hydrolyzes the probe through its 5'-3 'exonuclease activity , thereby separating the fluorescent indicator and the switch. This results in an increase in the fluorescence that is detected. During the thermal cycles of the real-time PCR reaction, the increase in fluorescence is monitored as it is released from the double-labeled probe hydrolyzed in each PCR cycle, allowing accurate determination of the final DNA amounts, and also initials.
  • miR-335 is detected by real-time PCR using the TaqMan (Applied Biosystems) probe as a double-labeled probe.
  • the levels of miR-335 can be quantified by comparison with an internal standard, for example, the level of messenger RNA (mRNA) of a maintenance or housekeeping gene present in the same sample or the level of a non-coding RNA of maintenance.
  • MRNA messenger RNA
  • MRNA that can be determined in accordance with the present invention include, but are not limited to, myosin, glyceraldehyde-3-phosphate dehydrogenase (GADPH) microglobulin ⁇ -2, ubiquitin, ribosomal protein 18S, cyclophilin, IP08, HPRT, PSMB4, tubulin , ⁇ -actin.
  • Non-coding RNAs that can be used as an internal standard include, without limitation, the RNAs U6, RNU19, RNU24, RNU38B, RNU43, RNU44, RNU48, RNU49, RNU58A, RNU58B, RNU66, RNU6B, RPL21, snoRNA135, snoRNA132, snoRNA202, snoRNA235 , snoRNA251, U6, U18, U47, U54, U75, U87, Z30, HY3, 5S rRNA and 4.5S RNA
  • the first method of the invention comprises determining the activity levels of miR-335.
  • miR-335 activity refers to the ability of miR-335 to inhibit the expression of a target gene. Therefore, miR-335 activity can be detected by assays in which the expression levels of its target genes are quantified.
  • miR-335 target genes are understood all those genes whose expression is directly regulated by miR-335.
  • miR-335 target genes when the expression of miR-335 target genes is increased in a stem cell, this implies that miR-335 activity levels are reduced in said stem cell.
  • miR-335 target genes when the expression of miR-335 target genes is decreased in a stem cell, this implies that miR-335 activity levels are high in said stem cell.
  • the miR-335 target genes are those that have in their coding region or in their 5 'or 3' UTR regions at least one miR-335 binding site.
  • Illustrative non-limiting examples of miR-335 target genes are those listed in Table 1.
  • ARID5B AT rich interactive domain 5B (MRF l-like)
  • DAAM1 Dishevelled associated activator of morphogenesis 1
  • NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
  • PARP14 Poly (ADP-ribose) polymerase family member 14
  • Sema domain immunoglobulin domain (Ig)
  • transmembrane domain immunoglobulin domain (Ig)
  • Sema domain Sema domain, transmembrane domain (TM), and cytoplasmic domain
  • SLC6A6 Solute carrier family 6 Neurotransmitter transporter, taurine
  • member 6 SLC6A6 Solute carrier family 6 (neurotransmitter transporter, taurine), member 6
  • TPD52L1 Tumor protein D52-like 1
  • the miR-335 target gene is RUNX2.
  • RUNX2 refers to a transcriptional factor involved in osteogenesis. There are three transcriptional variants of RUNX2, (GenBank Accession Numbers M_001015051, M_004348), and these variants have a miR-335 binding site in their 3 'UTR region. In this way, the expression of RUNX2 is negatively regulated by miR-335.
  • the miR-335 target gene is "SOX4".
  • SOX4 refers to a transcription factor involved in the regulation of progenitor cell development and migration (GeneBank Accession Number: M_003107.2).
  • the expression levels of the miR-335 target genes can be determined by analyzing the nucleic acid levels of said genes or by analyzing the levels of the encoded protein by said genes, using methods known in the art.
  • the nucleic acid levels of the miR-335 target genes for example, the RUNX2 and SOX4 genes
  • conventional techniques can be used to determine the expression levels of a given gene in a given cell, such as RT -PCR, Northern blot and the like to determine mRNA expression.
  • the first method of the invention can additionally include carrying out an extraction step in order to obtain the total RNA, which can be done by conventional techniques.
  • any conventional method can be used within the framework of the invention to detect and quantify mRNA levels encoded by the miR-335 target genes, (e.g., the RUNX2 and SOX4 genes) and their corresponding complementary DNA (cDNA) .
  • the levels of mRNA encoded by said genes can be quantified by the use of conventional methods, for example, methods comprising amplification of mRNA and quantification of the product of amplification of said mRNA, such as electrophoresis.
  • the level of cDNA corresponding to the mRNA encoded by the miR-335 target genes can also be quantified using conventional techniques; in this case, the method of the invention includes a step of synthesis of the corresponding cDNA by reverse transcription (RT) of the corresponding mRNA followed by amplification and quantification of the amplification product of said cDNA.
  • RT reverse transcription
  • Conventional methods for quantifying expression levels can be found, for example, in Sambrook et al, 2001, "Molecular cloning: a Laboratory Manual", 3rd ed., Cold Spring Harbor Laboratory Press, NY, Vol. 1-3.
  • the quantification of the expression level of the miR-335 target genes is performed by a polymerase chain reaction (PCR), in any of its variants.
  • miR-335 target genes can also be determined at the protein level, that is, by measuring the level of polypeptides encoded by said target genes. Such methods are well known in the art and include, but are not limited to, for example, Western Blot, ELISA, RIA, immunofluorescence, flow cytometry, etc., which use antibodies against proteins encoded by genes.
  • the expression level of the miR-335 target genes (for example, the RUNX2 and SOX4 genes) can be quantified by any conventional method that allows detecting and quantifying said proteins in a sample of a subject.
  • the levels of miR-335 target genes can be quantified, for example, by the use of antibodies capable of binding to the proteins encoded by said genes and subsequent quantification. of the complexes formed.
  • the antibodies used in these assays may or may not be labeled.
  • markers that can be used include radioactive isotopes, enzymes, fluorophores, chemiluminescent reagents, enzyme substrates or cofactors, enzyme inhibitors, particles, dyes, etc.
  • markers include radioactive isotopes, enzymes, fluorophores, chemiluminescent reagents, enzyme substrates or cofactors, enzyme inhibitors, particles, dyes, etc.
  • There is a wide variety of known assays that can be used in the present invention which use unlabeled antibodies (primary antibody) and labeled antibodies.
  • Secondary antibody secondary antibody
  • These techniques include Western blotting or Western blotting, ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), competitive EIA (competitive enzyme immunoassay), DAS-ELISA (ELISA sandwich with double antibody), immunocytochemical and immunohistochemical techniques , techniques based on the use of biochips or microarrays of proteins that include specific antibodies or tests based on colloidal precipitation in formats such as dipsticks.
  • Other ways to detect and quantify said miR-335 target gene proteins include affinity chromatography techniques, ligand binding assays, etc.
  • the quantification of the levels of the protein encoded by the miR-335 target genes is performed by western blot, ELISA, immunohistochemistry or an array of proteins.
  • reporter genes can also be used, that is, a DNA construct comprising the promoter of the gene under study operatively coupled to a reporter gene can be employed.
  • the alteration of the levels of the miR-335 target genes is an increase and, consequently, the change in expression in the reporter gene is indicative that miR-335 activity is being inhibited.
  • Reporter genes suitable for use in the present invention include luciferase.
  • the first method of the invention requires comparing the levels of expression and / or activity of miR-335 in a stem cell with a reference value.
  • the term "reference value”, as used in the present invention refers to a value that derives from a collection of samples consisting of stem cells of the same type as stem cells whose immunoregulatory capacity is being tested by The first method of the invention. Said collection of samples comes from a subject, preferably from two or more subjects, which is known to not have a disease that can be treated by administration of stem cells or, alternatively, of the general population.
  • the reference value can be an expression value or an activity value of miR-335.
  • the expression reference value of miR-335 is determined by techniques well known in the state of the art, for example, by isolating RNA from each sample of stem cells in the collection, determining miR-335 expression levels in each isolated RNA and calculating the average miR-335 expression levels determined in each sample of stem cells.
  • the reference value could be determined by measuring miR-335 expression levels in an RNA sample obtained by mixing equal amounts of RNA from each of the stem cell samples of the aforementioned collection.
  • the activity reference value of miR-335 can be determined by previously described techniques, that is, by determining the expression levels of miR-335 target genes (eg, RUNX2 and SOX4 genes) in each sample of stem cells of the collection and the calculation of the average of all values.
  • the reference value of miR-335 activity could be determined by measuring the expression levels of miR-335 target genes in a sample obtained by mixing equal amounts of each of the stem cell samples from the aforementioned collection.
  • the collection of stem cell samples to be analyzed to calculate the reference value is preferably derived from a population of two or more subjects; for example, the population may comprise 3, 4, 5, 10, 15, 20, 30, 40, 50 or more subjects.
  • the reference value may correspond to the levels of an RNA that is constitutively expressed in the cell and that does not show variations in its expression levels in high power stem cells or immunregulatory capacity with respect to stem cells that do not have High power or regulatory capacity.
  • Said reference RNA includes, for example, messenger RNA (mRNA) of a maintenance gene or "housekeeping" present in the same sample or the level of a non-coding maintenance RNA.
  • GIDPH glyceraldehyde-3-phosphate dehydrogenase
  • the reference RNA may also be non-coding RNAs such as, for example, RNAs U6, RNU19, RNU24, RNU38B, RNU43, RNU44, RNU48, RNU49, RNU58A, RNU58B, RNU66, RNU6B, RPL21, snoRNA142, snoRNA14, snoRNA2N, snoRNA2N2 snoRNA234, snoRNA251, U6, U18, U47, U54, U75, U87, Z30, HY3, 5S rRNA and 4.5S RNA.
  • a “subject”, as used herein, refers to a mammal, human or non-human, preferably a human being.
  • the subject can be any subject, a subject predisposed to a disease (for example, a disease capable of being treated with stem cells) or a subject suffering from said disease.
  • disease that can be treated with a stem cell includes, but is not limited to, an autoimmune disease, an inflammatory disease, graft versus host disease, a disease that requires induction of transplant tolerance or a disease that requires repair and / or tissue regeneration.
  • the first method of the invention comprises comparing the levels of expression and / or activity of miR-335 in a stem cell with said reference value, so that high levels with respect to the reference value are indicative. that said stem cell has a low immunoregulatory capacity, while decreased levels with respect to the reference value are indicative that said stem cell has a high immunoregulatory capacity.
  • high levels with respect to the reference value means any variation in the levels of expression and / or activity of miR-335 above the reference level.
  • a variation of the level of expression and / or activity of miR-335 above the reference value may be at least 1, 1 times, 1.5 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or even more compared to the reference value.
  • “decreased levels with respect to the reference value” means any variation in the levels of expression and / or activity of miR-335 below the reference value.
  • a variation of the expression level of miR-335 below the reference value may be at least 0.9 times, 0.75 times, 0.2 times, 0.1 times, 0.05 times, 0.025 times, 0 , 02 times, 0.01 times, 0.005 times or even less compared to the reference value.
  • the first method of the invention allows to determine whether the stem cell whose expression levels and / or miR-335 activity have been analyzed has a low or high capacity or immunoregulatory power. Additionally, the first method of the invention also allows determining whether said stem cell has a low or high therapeutic power.
  • the levels of expression and / or activity of miR-335 in a stem cell are high relative to the reference value, it is indicative that said stem cell has a low capacity or low immunoregulatory power.
  • the levels of expression and / or activity of miR-335 in a stem cell are high with respect to the reference value, it is indicative that said stem cell has a low therapeutic power.
  • the levels of expression and / or activity of miR-335 in a stem cell are decreased with respect to the reference value, it is indicative that said stem cell has a high immunoregulatory capacity or potency.
  • the levels of expression and / or activity of miR-335 in a stem cell are decreased with respect to the reference value, it is indicative that said stem cell has a high therapeutic power.
  • high or low refer to therapeutic potency and / or immunoregulatory capacity, refer to the suitability of a stem cell to be effective in the treatment of a certain disease. .
  • the invention in another aspect, relates to a method for selecting a batch of stem cells for therapeutic applications related to the immunoregulatory activity of said stem cells, wherein said method comprises determining in the stem cells of said batch the expression levels and / or activity of miR-335, where if the levels of expression and / or activity of miR-335 are lower than a reference value, the batch of stem cells is selected for therapeutic applications related to the immunoregulatory activity of said stem cells.
  • stem cells “miR-335", “miR-335 activity”, “miR-335 levels”, “high levels and / or expression” have been described in detail in relation to the first method of the invention and are equally applicable to the method of batch selection of stem cells.
  • graft versus host disease GVHD
  • autoimmune diseases inflammation, etc.
  • the invention in another aspect, relates to a method for selecting a batch of stem cells for therapeutic applications related to the immunoregulatory activity of said stem cells comprising determining the levels of expression and / or activity of miR335 in stem cells of said batch and in the stem cells of a control lot previously selected as suitable for therapeutic applications related to immunoregulatory activity, where if the levels of expression and / or activity of miR335 in the stem cells are similar to the levels of expression and / or activity of miR335 in the cells of the control lot, then the batch of stem cells is selected for therapeutic applications related to the immunoregulatory activity of said stem cells.
  • the methods for characterizing batches of stem cells of the invention comprise determining in the stem cells of said batch the levels of expression and / or activity of miR-335.
  • Suitable methods for carrying out said determination have been described in detail in the context of the first method of the invention and include, without limitation, methods based on the quantification of the miR-335 or methods based on the determination of the activity of the miR-335 , thereby determining the levels of gene expression whose expression is regulated by miR-335.
  • Such genes have been described in detail in Table 1 of the present invention.
  • the level of expression and / or activity of the miR-355 obtained in the first stage is compared with a reference value, wherein said reference value is a predetermined value or the value of the expression level and / or miR-355 activity in the stem cells of a control batch previously selected as suitable for therapeutic applications related to immunoregulatory activity.
  • stem cells of a control batch previously selected as suitable for therapeutic applications related to immunoregulatory activity refers to cells that have been identified as suitable for use in activity related applications. immunoregulatory, using either the determination of the levels or activity of miR-335 according to the first method of the invention or by any of the potency tests commonly used to release batches of stem cells for use in therapy.
  • the cells in the control lot are cells that have one or more of the following properties:
  • They are cells that have reduced levels of activity and / or expression of miR-335, according to the present invention.
  • potency assays that can be used to select a batch of control cells include, for example, the assays mentioned by Bieback et al. (Transfus. Med. Hemother. 2008; 35: 286-294) including:
  • the cells that are selected as a control lot as suitable for therapeutic applications related to the immunoregulatory activity are autologous, syngeneic, allogeneic or xenogeneic with respect to the cells of the batch to be selected.
  • the potency assay according to the present invention is used as a potency assay within the regulatoryly accepted release criteria of batches of stem cells for therapeutic applications.
  • the batch stem cell is an adult stem cell.
  • the adult stem cell is an adult stem cell of mesenchymal origin.
  • the adult mesenchymal stem cell is derived from bone marrow or subcutaneous adipose tissue. Invention kit
  • the invention relates to a kit, hereafter kit of the invention, to determine the immunoregulatory capacity of a stem cell comprising
  • suitable reagents for determining the expression level of miR-335" is meant any reagent necessary to specifically detect the expression of miR-335 by the detection methods previously described in the context of the first method of the invention.
  • the reagents suitable for determining the level of miR-335 expression are one or more pairs of oligonucleotides specifically designed to amplify miR-335 using the methods of the invention in an RT-PCR assay, preferably a real-time RT-PCR assay.
  • suitable reagent to determine the level of expression of a reference RNA is meant any reagent necessary to specifically detect the expression of an RNA by any of the detection methods previously described in the context of the first method of the invention.
  • the reagents suitable for determining the level of expression of a reference RNA are one or more pairs of oligonucleotides specifically designed to amplify said RNA or probes that specifically hybridize with said RNA.
  • the determination of RNA levels is carried out by an RT-PCR assay, preferably a real-time RT-PCR assay.
  • the reference RNA is the messenger RNA (mRNA) of a housekeeping or maintenance gene.
  • MRNA messenger RNA
  • MRNA messenger RNA
  • GADPH glyceraldehyde-3-phosphate dehydrogenase
  • microglobulin ⁇ -2 ubiquitin
  • ribosomal protein 18S ribosomal protein 18S
  • cyclophilin IP08
  • HPRT HPRT
  • PSMB4 tubulin
  • tubulin ⁇ -actin.
  • the reference RNA may also be a non-coding RNA such as, for example, RNAs U6, RNU19, RNU24, RNU38B, RNU43, RNU44, RNU48, RNU49, RNU58A, RNU58B, RNU66, RNU6B, RPL21 , snoRNA135, snoRNA142, snoRNA202, snoRNA234, snoRNA251, U6, U18, U47, U54, U75, U87, Z30, HY3, 5S rRNA and 4.5S RNA.
  • the kit of the invention additionally comprises reagents suitable for determining the expression and / or activity levels of a marker of the immunoregulatory capacity and / or a senescence marker in said stem cell.
  • Markers of the immunoregulatory capacity of a stem cell are selected from the group consisting of MHC class I, MHC class II, CD40, CD80 (B71), CD86 (B72), B7-DC (PD-L2), B7H1 (PD- L1), B7H2 (CD275 / ICOSL), B7H3 (CD276), B7H4 (VTCN1), B7H5, B7H6, B7H7.
  • the immunoregulatory capacity marker of a stem cell is B7H1.
  • the senescence marker is selected from the group consisting of ⁇ -galactosidase, Ki67, p21 (CDKN1A), ⁇ 2 ⁇ , SAHF, p53 and, Lamin B.
  • the senescence marker of a stem cell is ⁇ -galactosidase.
  • ⁇ -galactosidase as a marker of cellular senescence is based on the detection of ⁇ -galactosidase activity at suboptimal pH. Lysosomal ⁇ -galactosidase is active at pH 4, but in senescent cells, due to the characteristic increase in lysosome mass in that state, there is an increase in ⁇ -galactosidase activity that allows its detection at pH 6.
  • Suitable reagents to measure ⁇ -galactosidase activity are those that allow the detection of ⁇ -galactosidase activity at pH 6, and are known to the person skilled in the art.
  • These reagents can include, but are not limited to, fixation solutions, staining solutions and artificial substrates of the enzyme which, after being hydrolyzed by ⁇ -galactosidase, release a chromogenic substance that can be observed through microscopy techniques.
  • fixation solutions staining solutions
  • artificial substrates of the enzyme which, after being hydrolyzed by ⁇ -galactosidase, release a chromogenic substance that can be observed through microscopy techniques.
  • These compounds are generally derivatives of galactopyranosides.
  • kits of the invention examples include, but are not limited to: nitro-phenyl-B-Dgalactopyranoside (O PG), red chlorophenyl BD-galactopyranoside (CPRG), bromine -chloroindolyl BD-galactopyranoside (X-gal), fluoresein di-BD-galactopyranoside (FDG) and the galacton substrate.
  • O PG nitro-phenyl-B-Dgalactopyranoside
  • CPRG red chlorophenyl BD-galactopyranoside
  • X-gal bromine -chloroindolyl BD-galactopyranoside
  • FDG fluoresein di-BD-galactopyranoside
  • the kit of the invention comprises X-gal as a suitable reagent to determine the levels of expression and / or activity of ⁇ -galactosidase.
  • the invention relates to a kit according to the invention to determine the immunoregulatory capacity or potency of a stem cell or to select a batch of stem cells for therapeutic applications related to the immunoregulatory activity of said stem cells.
  • the invention relates to an in vitro method, hereinafter second method of the invention, to increase the immunoregulatory capacity of a stem cell, which comprises inhibiting in said stem cell the expression and / or activity of miR -335.
  • the second method of the invention comprises inhibiting the expression and / or activity of miR-335 in a stem cell.
  • miR-335 inhibitor refers to any agent or small molecule that inhibits, reduces or decreases the expression and / or activity of miR-335.
  • the miR-335 hybrid inhibitor with miR-335 and thus inhibits its activity.
  • miR-335 inhibitors include: antisense oligonucleotides, interference RNA (RNAi), ribozymes, DNA enzymes, natural or synthetic small compounds, preferably small organic compounds, etc.
  • Antisense oligonucleotides are simple strands of DNA or RNA that are complementary to a chosen sequence. Antisense RNAs prevent translation of proteins by joining their messenger RNAs. Antisense DNAs can bind to a specific and complementary sequence of RNA (coding or non-coding), resulting in a DNA / RNA hybrid that can be degraded by the enzyme RNase H.
  • a construct which comprises an antisense oligonucleotide can be distributed, for example, as an expression plasmid which, when transcribed in the cell, produces RNA that is complementary at least in part to the miR-335 sequence.
  • the antisense construct can be an oligonucleotide probe that is generated ex vivo and that, when introduced into the cell, hybridizes with miR-335 preventing its function.
  • oligonucleotide probes are preferably modified oligonucleotides, which are resistant to endogenous nucleases, for example, exonucleases and / or endonucleases, and which are therefore stable in vivo.
  • Illustrative nucleic acid molecules for use as antisense oligonucleotides include phosphoramidate, phosphothionate and methylphosphonate DNA analogs (see, for example, US5176996, US5264564 and US5256775).
  • in vitro studies should be performed to quantify the ability of antisense oligonucleotides to inhibit the function of miR-335.
  • said studies will use controls that distinguish between antisense gene inhibition and non-specific biological effects of oligonucleotides. It is also preferred that these studies compare the levels of the target RNA or protein with those of an internal control of RNA or protein. The results obtained using the antisense oligonucleotides can be compared with those obtained using a control oligonucleotide.
  • control oligonucleotide be approximately the same length as the oligonucleotide to be tested and that the oligonucleotide sequence differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.
  • the antisense oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single chain or double chain.
  • the oligonucleotide can be modified in the base, in the sugar or in the phosphate skeleton, for example, to improve the stability of the molecule, its hybridization capacity etc.
  • the oligonucleotide may include other bound groups, such as peptides (for example, to direct them to host cell receptors) or agents to facilitate transport across the cell membrane (Letsinger et al, Proc. Nati. Acad. Sci. USA 86 : 6553-6556, 1989; Lemaitre et al, Proc. Nati. Acad. Sci.
  • the oligonucleotide may be conjugated to another molecule, for example, a peptide, a transport agent, a hybridization triggered cutting agent, etc.
  • a preferred approach uses a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter.
  • the mir-335 inhibitor can be an interference RNA.
  • An interference RNA is an RNA that modulates the expression of a gene through the mechanism of RNA interference.
  • the RNAi is a small RNAi.
  • Small interference RNAs or siRNAs are agents capable of inhibiting the expression of a target gene by RNA interference.
  • An siRNA can be chemically synthesized, or, alternatively, it can be obtained by in vitro transcription or it can be synthesized in vivo in the target cell.
  • siRNAs consist of a double strand of RNA between 15 and 40 nucleotides in length, which may contain a 3 'and / or 5' protruding region of 1 to 6 nucleotides. The length of the protuberant region is independent of the total length of the siRNA molecule.
  • SiRNAs act by degradation or post-transcriptional silencing of the target messenger.
  • the siRNAs can be called shRNA (short hairpin RNA), characterized in that the antiparallel chains that form the siRNA are connected by a loop or hairpin region.
  • shRNAs may be encoded by plasmids or viruses, particularly retroviruses, and be under the control of promoters such as the U6 promoter of RNA polymerase III.
  • the siRNAs that can be used in the present invention are substantially homologous to miR-335.
  • substantially homologs are understood to have a sequence that is sufficiently complementary or similar to the miR-335 sequence, such that the siRNA is capable of causing degradation by RNA interference.
  • Suitable siRNAs to cause such interference include formed siRNAs. by RNA, as well as siRNA that contain different chemical modifications such as:
  • RNA chain conjugates with a functional reagent such as a fluorophore
  • nucleotides with modified sugars such as 2'-0-methylribose or 2'-0-fluorosibose O-alkylated moieties;
  • nucleotides with modified bases such as halogenated bases (for example 5-bromouracil and 5-iodouracil), alkylated bases (for example 7-methylguanosine).
  • modified bases such as halogenated bases (for example 5-bromouracil and 5-iodouracil), alkylated bases (for example 7-methylguanosine).
  • siRNAs and siRNAs that can be used in the present invention can be obtained using a series of techniques known to the person skilled in the art.
  • the miR-335 inhibitor is a ribozyme specifically designed to catalytically cut the miR-335 sequence.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cut of RNA [for a review see Rossi, 1994. Current Biology 4: 469-471].
  • the sequence of ribozyme molecules preferably includes one or more sequences complementary to the target RNA, this is miR-335, and the well-known sequence responsible for RNA cutting or a functionally equivalent sequence [see, for example, US5093246].
  • Ribozymes may be composed of modified oligonucleotides (for example, to improve stability, targeting, etc.) and should be distributed to cells expressing the target gene in vivo.
  • a preferred method of distribution involves using a DNA construct that "encodes" the ribozyme under the control of a strong constitutive promoter of pol III or pol II, so that the transfected cells will produce sufficient amounts of the ribozyme to destroy the endogenous target messengers and inhibit translation. Since ribozymes, contrary to other antisense molecules, are catalytic, a lower intracellular concentration is required to be effective.
  • the miR-335 inhibitor is a DNA enzyme.
  • DNA enzymes incorporate some of the mechanistic characteristics of both antisense oligonucleotide technologies and ribozyme technologies. DNA enzymes are designed to recognize a particular nucleic acid target sequence (in this case, the miR-335 sequence), similar to the antisense oligonucleotide; however, similar to ribozyme, they are catalytic and specifically cut the target nucleic acid.
  • the miR-335 inhibitor is a nucleic acid, for example, an antisense oligonucleotide or an RNAi.
  • the miR-335 inhibitor is single chain polynucleotide that has the ability to specifically hybridize with miR-335 preventing its function. By “preventing its function” is meant to block at least partially the activity of miR-335.
  • the miR-335 inhibitor can be introduced into the target cell using any suitable protocol.
  • the miR-335 inhibitor is a nucleic acid, such as an antisense oligonucleotide or an RNAi
  • it can be introduced into the target cell using any known technique of transferring nucleic acids to cells in vitro.
  • Such techniques include, but are not limited to, electroporation, nucleofection, lipofection, calcium phosphate mediated transfection, magnetofection, or viral infection (transduction).
  • the transfer procedure includes the transfer of a selectable marker to the cells. The cells are then screened to isolate the cells that have incorporated and express the transferred gene.
  • the transfer of the miR-335 inhibitor nucleic acid to the target cell can be transient or stable.
  • the transfer is stable, so that the nucleic acid is expressible by the cell and preferably inheritable and expressible by its cellular progeny.
  • the miR-335 inhibitor nucleic acid is transferred to the stem cell by lipofection with a reagent such as Lipofectamine 2000 (Invitrogen).
  • the stem cell whose immunoregulatory capacity is to be increased is an adult stem cell, preferably a mesenchymal stem cell, more preferably a mesenchymal stem cell from bone marrow or subcutaneous adipose tissue.
  • stem cells specifically the use of MSC
  • MSC myeloma
  • Phase I / II clinical trials are being developed to study its use in the treatment of Crohn's disease and multiple sclerosis and it is planned to begin them in the treatment of systemic lupus erythematosus, systemic sclerosis, systemic vasculitis, type 1 diabetes and others.
  • Many immune based diseases are being developed to study its use in the treatment of Crohn's disease and multiple sclerosis and it is planned to begin them in the treatment of systemic lupus erythematosus, systemic sclerosis, systemic vasculitis, type 1 diabetes and others. Many immune based diseases.
  • MSCs ability to interact with cells of the immune system to control an immune response is also known from the state of the art, which in the case of autoimmune diseases, is responsible for the destruction of different tissues or specific cells causing their deterioration. In these cases, the use of MSC manages to energize the T, B and NK lymphocytes, achieving an asymptomatic state free of immunosuppressive medications.
  • the present invention relates to a stem cell characterized in that it exhibits reduced levels of expression and / or activity of miR-335 for use in medicine.
  • the present invention also relates to a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 for use in the treatment of an autoimmune disease, of an inflammatory disease, of graft versus disease. host, in induction of transplant tolerance or in tissue repair and regeneration.
  • the invention also relates to a method, hereinafter the therapeutic method of the invention, for the treatment of an autoimmune disease, an inflammatory disease, graft versus host disease, type 1 diabetes, diabetes type 2, of a cardiovascular disease, for the induction of transplant tolerance, or for the repair and regeneration of tissues in a subject, which comprises administering to said subject a therapeutically effective amount of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335.
  • the present invention also relates to a use of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 with respect to a reference value for preparing a medicament for the treatment of a disease selected from the group formed by an autoimmune disease, an inflammatory disease and graft versus host disease.
  • inflammatory disease includes any disease caused by uncontrolled and continued activation of inflammatory responses that cause tissue damage; Said inflammatory response can be triggered by infectious agents, physical agents, chemical agents, tumors and cell death. "Autoimmune diseases”, to the extent that they also have an inflammatory component, fall within the term “inflammatory diseases” as used herein.
  • inflammatory diseases and autoimmune diseases include, Addison's disease, alopecia areata, ankylosing spondylitis, hemolytic anemia, pernicious anemia, thrush, aphthous stomatitis, arthritis, arteriosclerosis, osteoarthritis, rheumatoid arthritis, aspermiogenesis, bronchial asthma autoimmune asthma, autoimmune hemolysis, Bechet's disease, Boeck's disease, inflammatory bowel disease, Burkitt's lymphoma, Crohn's disease, chorioiditis, ulcerative colitis, celiac disease, cryoglobulinemia, dermatitis herpetiformis, dermatomyositis, insulin-dependent diabetes, juvenile diabetes, diseases autoimmune demielinizers, Dupuytren's contracture, encephalomyelitis, allergic encephalomyelitis, endophthalmia, allergic enteritis, autoimmune enter
  • graft versus host disease refers to a syndrome observed after an allogeneic hematopoietic stem cell transplant and presumably transmitted by the donor's T lymphocytes when reacting against the recipient's tissues.
  • EICH can be acute or chronic.
  • type 1 diabetes also called “type I diabetes mellitus” or "juvenile diabetes” or “insulin dependent diabetes mellitus”, as used in the context of the present invention, is a metabolic disease characterized by destruction Selective beta cells of the pancreas causing an absolute insulin deficiency.-It differs from type 2 diabetes because it is a type of diabetes characterized by occurring early in life, usually before age 30. Only 1 in 20 people with diabetes have type I diabetes, which occurs most frequently in young people and children. Insulin administration in these patients is essential. Type 1 diabetes is classified into autoimmune cases — the most common form — and in idiopathic cases. The susceptibility to type 1 diabetes mellitus seems to be associated with multiple genetic factors, although only 15-20% of patients have a positive family history.
  • type 2 diabetes refers to a disease characterized by an inappropriate elevation of blood glucose levels that causes chronic complications due to the involvement of large and small vessels and nerves.
  • the underlying alteration in this disease is the difficulty for the action of insulin (such as a loss of tissue sensitivity to this hormone) that is called insulin resistance and an inadequate secretion of insulin by the cells responsible for its production in the pancreas.
  • insulin resistance the difficulty for the action of insulin (such as a loss of tissue sensitivity to this hormone) that is called insulin resistance and an inadequate secretion of insulin by the cells responsible for its production in the pancreas.
  • insulin resistance an inadequate secretion of insulin by the cells responsible for its production in the pancreas.
  • the deficient action of insulin often results in elevated cholesterol and / or triglyceride levels.
  • cardiovascular disease refers to any disease or dysfunction or alteration of the heart or of the rest of the cardiovascular or blood system.
  • the immunomodulatory capacity of the stem cells not only has importance in the treatment of inflammatory, autoimmune diseases and in the treatment of graft versus host disease, but they are also outlined as an indispensable treatment element to promote tolerance towards solid organs such like the heart, lung and kidney; By way of illustration, co-infusion of stem cells is possible at the time of transplantation.
  • the present invention also relates to a use of a stem cell characterized in that it exhibits reduced levels of expression and / or activity of miR-335 to prepare a medicament to induce transplant tolerance.
  • the stem cells Once the stem cells enter the bloodstream, they are able to detect molecules that are secreted by damaged or dying tissues in what is known as the "homing" or nesting phenomenon. Once it is in close proximity to the tissue damaged, the stem cell adheres to the surface of the organ through molecular receptors that it expresses on the surface of the cell membrane.This starts a series of events that allow the stem cell to integrate into the damaged organ and begin to secrete factors of growth that stimulate locally Resident stem cells of the affected organ itself, in addition to changing the inflammatory microenvironment to give rise to a microenvironment permissible for cell regeneration, where a process of cell fusion or differentiation begins then becoming a physiologically mature cell, in addition to promoting the formation of New blood vessels Therefore, in another aspect, the invention relates to a use of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 with respect to a reference value for preparing a medicament for tissue repair and regeneration.
  • the stem cell according to the therapeutic uses and methods of the invention is preferably an adult stem cell, more preferably a mesenchymal stem cell, even more preferably a mesenchymal stem cell of bone marrow or subcutaneous adipose tissue.
  • the stem cell is modified by a miR-335 inhibitor.
  • miR-335 inhibitor as well as the methods for incorporating said inhibitor into the stem cell have been previously described in the context of the second method of the invention.
  • the miR-335 inhibitor is preferably a single chain polynucleotide that specifically hybridizes with miR-335 preventing its function. More preferably, the miR-335 inhibitor contains the sequence SEQ ID No: 1 or a clearly related sequence.
  • nuclearly related sequence includes functionally equivalent sequences, that is, sequences having an identity with the sequence SEQ ID NO: 1 of at least 85%, typically at least 90%, advantageously at least 95%, preferably at least 99%, and maintain the ability to hybridize with miR-335 and prevent its function. Illustrative tests to detect the levels of expression and / or activity of miR-335 have been previously exposed so that the person skilled in the art could easily identify if a sequence is clearly related to the sequence shown in SEQ ID NO: 1, or is functionally equivalent to it.
  • the cells according to the therapeutic uses and methods of the invention have reduced levels of expression and / or activity of miR-335.
  • reduced levels of expression and / or activity of miR-335" refer to reduced levels of expression and / or activity of said miR-335 with respect to a value of reference.
  • Reduced levels of expression and / or activity with respect to the reference value means any variation in the levels of expression and / or activity of miR-335 below the reference value.
  • a variation of the level of expression and / or activity of miR-335 below the reference value may be at least 0.9 times, 0.75 times, 0.2 times, 0, 1 times, 0.05 times, 0.025 times, 0.02 times, 0.01 times, 0.005 times or even less compared to the reference value.
  • the stem cell according to the therapeutic uses and methods of the invention can be autologous, allogeneic or xenogeneic with respect to the subject to be treated.
  • autologous means that the donor and the recipient of the stem cell is the same subject.
  • allogeneic means that the donor and the recipient of the stem cell are different subjects.
  • xenogeneic means that the donor and the recipient of the stem cell are subjects of different species.
  • the therapeutic method of the invention comprises administering to a subject a therapeutically effective amount of a stem cell characterized in that it has reduced levels of expression and / or activity of miR-335 with respect to a reference value.
  • therapeutically effective amount of a stem cell in the context of the therapeutic method of the invention, is meant an amount of a stem cell, or a population of substantially homogeneous stem cells, which is capable of producing the desired therapeutic effect, and in In general, it will be determined, among other factors, taking into account the characteristics of the subject, the severity of the disease, the form of administration, etc. For this reason, the doses mentioned in this invention should be taken into account only as a guide for the person skilled in the art, who should adjust that dose depending on the factors described above.
  • the stem cells according to the uses and therapeutic methods of the invention can be administered as a single dose, containing from about lxl 0 5 to about 10x10 6 stem cells of the invention per kilogram (kg) of body weight of the recipient, preferably between about 5xl0 5 and about 5xl0 6 stem cells of the invention per kg of body weight of the recipient, more preferably between about lxl O 6 and about 2x10 6 stem cells of the invention per kg of body weight of the receptor, depending on the factors described above.
  • the dose of stem cells according to the therapeutic uses and methods of the invention can be repeated, depending on the state and evolution of the subject, in time intervals of days, weeks or months that the specialist must establish in each case.
  • stem cell can be administered to said subject intravenously using suitable devices, such as syringes, catheters (a standard peripheral intravenous catheter, a central venous catheter or a pulmonary arterial catheter, etc.), trocars, cannulas, etc.
  • suitable devices such as syringes, catheters (a standard peripheral intravenous catheter, a central venous catheter or a pulmonary arterial catheter, etc.), trocars, cannulas, etc.
  • the flow of the cells can be controlled by inflating and deflating in series of distal and proximal balloons located within the vasculature of the subject, thus creating temporary areas without flow that promote cellular therapeutic action.
  • the stem cell will be administered using the equipment, apparatus and devices suitable for the administration of cellular compositions and known to those skilled in the art.
  • direct administration of the stem cell according to the therapeutic uses and methods of the invention to the site that is intended to benefit can be advantageous.
  • direct administration of said stem cells to the desired organ or tissue can be achieved by direct administration (eg, by injection, etc.) on the external surface of the affected organ or tissue by insertion of a suitable device, eg , an appropriate cannula, by arterial or venous perfusion (including retrograde flow mechanisms) or by other means known in the art.
  • Stem cells according to the therapeutic uses and methods of the invention can be stored until the moment of their application by conventional procedures known to those skilled in the art.
  • short-term storage (less than 6 hours)
  • said cells can be stored at or below room temperature in a sealed container, complementing it or not with a nutrient solution.
  • Medium-term storage (less than 48 hours) is preferably carried out at 2-8 ° C, in an iso-osmotic solution and buffered in a container composed of, or coated with, a material that prevents cell adhesion.
  • Longer term storage is preferably carried out by means of Proper cryopreservation and storage under conditions that promote retention of cellular function.
  • Stem cells according to the therapeutic uses and methods of the invention can be used in a combination therapy with other additional compounds that may be useful for the treatment of the disease to be treated.
  • Said additional compounds may be administered together with said stem cells as part of the same composition or, alternatively, they may be administered in the form of a separate composition for simultaneous or successive administration (sequential in time) with respect to the administration of the cells mother according to the therapeutic uses and methods of the invention.
  • the invention relates to an in vitro method, hereinafter third method of the invention, for generating regulatory T cells, which comprises contacting a population of cells containing T cells with a population of stem cells characterized in that they have reduced levels of expression and / or activity of miR-335 under conditions suitable for the generation of regulatory T cells.
  • regulatory T cells refers to T cells whose main function is to control inflammation and maintain self-tolerance by expanding and controlling the activation of autoreactive CD4 + effector T cells. Regulatory T cells are primarily between the subpopulation of CD4 + T cells that exhibit high levels of CD25 expression and Foxp3 transcription factor. Specifically, the subpopulations CD4 + CD25 + alt0 Foxp3 + (Treg cells), CD4 + IL10 + Foxp3- (Trl cells) and CD4 + TGF-p + (Th3 cells) are considered regulatory cells.
  • CD8 + T cells such as subpopulations CD8 + CD25 +, CD8 + CD28- and CD8 + IL-10 +, which are also capable of repressing activation and lymphocyte proliferation, and therefore are included within the definition of regulatory T cells according to the third method of the invention.
  • the third method of the invention comprises contacting a population containing T cells with stem cells.
  • the population containing T cells is a population of peripheral blood mononuclear cells.
  • peripheral blood mononuclear cells or "PBMC” include lymphocytes, monocytes and macrophages. Methods for isolating these PBMCs from a blood sample are well known in the art.
  • the population containing T cells is a population of PBMC that has been enriched in CD4 + lymphocytes, either in CD8 + lymphocytes or in both types of CD4 + and CD8 + lymphocytes.
  • Stem cells exhibiting reduced levels of expression and / or activity of miR-335 have been previously described, in the context of the therapeutic uses and methods of the invention.
  • Said stem cells are preferably adult stem cells, more preferably mesenchymal stem cells.
  • the population of T cells and the stem cells must be co-cultured under conditions suitable for the generation of regulatory T cells.
  • Suitable conditions for the generation of regulatory T cells are those that allow obtaining T cells capable of carrying out the functions of regulatory T cells, such as inhibition of mixed lymphocyte reaction (MLR), and are known by the skilled.
  • MLR mixed lymphocyte reaction
  • the “mixed lymphocyte reaction” or “MLR” is an in vitro method to analyze the proliferation of helper T cells. Said method consists in the co-culture of allogeneic lymphocytes, which causes the expansion of the helper T cell population. Regulatory T cells, when added to a culture of an MLR, are capable of inhibiting the proliferation of said helper T lymphocytes.
  • a population containing T cells with a population of stem cells characterized by having reduced levels of expression and / or activity of miR-335 is co-cultivated, regulatory T cells are obtained which, when added to an MLR are able to inhibit the proliferation of helper T lymphocytes.
  • Said inhibition of T helper lymphocyte proliferation can be at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at minus 70%, at least 80%, at least 90%, at least 95% or even 100%.
  • suitable conditions for the generation of regulatory T cells consist of co-culture of stem cells, preferably MSC, with a population containing T cells, preferably a population of PBMC, for a period of time of 1 to 5 days, preferably 4 days.
  • Co-cultures can be carried out using different proportions of MSC and T cells, for example, 1: 2, 1: 20, 1: 200, 1: 2000 and 1: 20000. In a preferred embodiment, the ratio of MSC and T cells is 1: 2000.
  • agents that stimulate the activation of regulatory T cells can be added during the co-culture of the stem cell population with the population containing T cells, in addition to the activation signals provided by the stem cells.
  • Agents that stimulate T cell activation may be antibodies, chemical stimuli of T cell function and inhibitors of T cell inhibition.
  • co-culture of the stem cell population with The population that contains T cells can be made with an antigen so that the expansion of antigen-specific regulatory T cells is induced.
  • the antigen can be an autoantigen.
  • the population of stem cells may be autologous or allogeneic with respect to the population containing T cells.
  • autologous refers to the population of cells mother and the population that contains T cells are derived from the same subject.
  • allogeneic refers to the fact that the population of stem cells and the population containing T cells are derived from different subjects. The term subject has been previously described.
  • Bone marrow and subcutaneous adipose tissue hMSC were isolated from human donors of different ages (between 18 and 55 years). After being cultured ex vivo under standard conditions (low glucose DMEM, 10% fetal bovine serum, 5 mM glutamine, at 37 ° C in an incubator with 5% C0 2 and 95% humidity) for one week, they were collected and were used for the isolation of total RNA by the miRNAeasy kit (Qiagen), following the manufacturer's instructions. The relative expression levels of miR-335 were quantified in the different RNA samples by real-time PCR using TaqMan (Applied Biosystems) probes. As endogenous control, U6 was used.
  • Figure 1 shows the relative expression levels of miR-335 in hMSC from donors of different ages. It can be clearly seen that the hMSCs of older donors have significantly higher endogenous levels of miR-335 than the hMSCs of younger donors. This suggests that miR-335 could be a positive marker of cellular senescence in hMSC, and therefore a negative marker of the therapeutic capacity of said cells.
  • Cellular senescence in culture is usually measured by the expression of ⁇ -galactosidase. A higher percentage of positive cells for said expression indicates a higher level of cell senescence.
  • Overexpression of miR-335 was induced in two different bone marrow hMSC isolates by transduction with a lentiviral vector encoding said miRNA. The same hMSC transduced with the same lentiviral vector but without coding miR-335 was used as a negative control. After isolating the transduced cells by flow cytometry, ⁇ -galactosidase expression levels were measured by specific staining using a commercial kit (Stemgent). The number of ⁇ -galactosidase positive cells was quantified by direct observation under a microscope.
  • the exogenous overexpression of miR-335 induces a significantly higher level of cellular senescence in bone marrow hMSC.
  • MiR-335 levels in senescent hMSC.
  • Bone marrow hMSC was transduced with a lentiviral vector encoding the catalytic subunit of human telomerase (hTERT). With this, it was achieved that said cells possess telomerase activity (which they lack under physiological conditions). The telomeric length in said transduced cells and in control cells was measured by a specific quantitative PCR assay, as well as the relative expression of miR-335 by RT-PCR.
  • Bone marrow hMSC were cultured under standard conditions (20% 0 2 ) or 3% of 0 2 , for 10 days. Next, the RNA from both cultures was isolated and the relative level of miR-335 was quantified by the method already described.
  • miR-335 expression levels decrease in hMSC grown at 3% of 0 2 , compared to those grown at 20%) of 0 2 . This result also confirms that miR-335 can be considered as a positive marker of cellular senescence.
  • PBMCs Human peripheral blood mononuclear cells
  • PBMCs Human peripheral blood mononuclear cells
  • HMSCs transduced with a lentiviral vector encoding miR-335 and control hMSCs were tested in parallel (transduced with a similar lentiviral vector that does not encode said miRNA).
  • mice received by the same route 10 6 hMSC or physiological serum (negative control).
  • One group of animals received hMSC transduced with a lentiviral vector encoding miR-335 and another control hMSC group (transduced with a similar lentiviral vector that does not encode said miRNA).
  • Experimental groups consisting of 10 animals each were used. Subsequently, the survival of the animals was monitored during the 96 hours following the administration of the LPS.
  • mice that received the control cells showed a survival greater than 80%, compared to a mortality of 100% in the mice that did not receive cells.
  • the animals that received the hMSC that expressed miR-335 showed significantly lower survival (less than 40%, Figure 6). This result also points to the value of miR-335 as a negative marker of the immunoregulatory capacity of hMSC.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes pour déterminer la puissance thérapeutique et la capacité immunorégulatrice de cellules mères basées sur les niveaux d'expression du micro-ARN miR-335. Cette détermination peut être utilisée comme critère pour la libération de lots de cellules mères en vue de leur utilisation en thérapie. En outre, l'invention concerne des méthodes in vitro pour augmenter la capacité immunorégulatrice d'une cellule mère, lesdites méthodes consistant à traiter ladite cellule mère avec un inhibiteur de miR-335. Enfin, l'invention concerne des utilisations et des méthodes thérapeutiques pour traiter un sujet atteint d'une maladie autoimmune, une maladie inflammatoire, la maladie du greffon contre l'hôte, ou une maladie qui nécessite l'induction d'une tolérance à la greffe ou la régénération et/ou la réparation de tissus, lesdites utilisations et méthodes thérapeutiques comprenant l'administration d'une cellule mère qui présente des niveaux réduits d'expression et/ou d'activité de miR-335.
PCT/ES2013/070381 2012-06-12 2013-06-12 Marqueur moléculaire de puissance thérapeutique de cellules mères mésenchymales humaines et ses utilisations WO2013186418A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201230919 2012-06-12
ES201230919A ES2434853B1 (es) 2012-06-12 2012-06-12 Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos

Publications (2)

Publication Number Publication Date
WO2013186418A1 true WO2013186418A1 (fr) 2013-12-19
WO2013186418A9 WO2013186418A9 (fr) 2014-04-17

Family

ID=49034107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2013/070381 WO2013186418A1 (fr) 2012-06-12 2013-06-12 Marqueur moléculaire de puissance thérapeutique de cellules mères mésenchymales humaines et ses utilisations

Country Status (2)

Country Link
ES (1) ES2434853B1 (fr)
WO (1) WO2013186418A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170101147A (ko) * 2016-02-26 2017-09-05 에스씨엠생명과학 주식회사 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111979187B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种抗人间充质干细胞衰老及增强其干性特征的方法

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009810A1 (fr) 1987-06-11 1988-12-15 Synthetic Genetics Nouveaux conjugues d'acide nucleique amphiphile
WO1989010134A1 (fr) 1988-04-25 1989-11-02 The Regents Of The University Of California Peptides chimeriques d'administration de neuropeptides a travers la barriere vasculaire du cerveau
US5093246A (en) 1986-12-03 1992-03-03 University Patents, Inc. Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5928907A (en) 1994-04-29 1999-07-27 The Perkin-Elmer Corporation., Applied Biosystems Division System for real time detection of nucleic acid amplification products
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
US6355420B1 (en) 1997-02-12 2002-03-12 Us Genomics Methods and products for analyzing polymers
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
US6458583B1 (en) 1998-09-09 2002-10-01 Agilent Technologies, Inc. Method and apparatus for making nucleic acid arrays
US6461816B1 (en) 1999-07-09 2002-10-08 Agilent Technologies, Inc. Methods for controlling cross-hybridization in analysis of nucleic acid sequences
US6465183B2 (en) 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
US6524793B1 (en) 1995-10-11 2003-02-25 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6632526B1 (en) 1997-10-14 2003-10-14 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
US6891032B2 (en) 1997-08-06 2005-05-10 Ambion, Inc. Methods and compositions for stripping nucleic acids
US6916661B2 (en) 1999-08-17 2005-07-12 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
US7026124B2 (en) 1998-09-09 2006-04-11 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US7052841B2 (en) 1999-11-08 2006-05-30 Agilent Technologies, Inc. Systems, tools and methods of assaying biological materials using spatially-addressable arrays
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
US7122303B2 (en) 1999-09-17 2006-10-17 Agilent Technologies, Inc. Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same
WO2011048222A1 (fr) * 2009-10-23 2011-04-28 Cellerix S.A. Populations cellulaires ayant une activité immunorégulatrice, procédés de préparation et utilisations associés

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093246A (en) 1986-12-03 1992-03-03 University Patents, Inc. Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods
WO1988009810A1 (fr) 1987-06-11 1988-12-15 Synthetic Genetics Nouveaux conjugues d'acide nucleique amphiphile
WO1989010134A1 (fr) 1988-04-25 1989-11-02 The Regents Of The University Of California Peptides chimeriques d'administration de neuropeptides a travers la barriere vasculaire du cerveau
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5928907A (en) 1994-04-29 1999-07-27 The Perkin-Elmer Corporation., Applied Biosystems Division System for real time detection of nucleic acid amplification products
US6015674A (en) 1994-04-29 2000-01-18 Perkin-Elmer Corporation Applied Biosystems Division Apparatus and method for detecting nucleic acid amplification products
US6524793B1 (en) 1995-10-11 2003-02-25 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
US6355420B1 (en) 1997-02-12 2002-03-12 Us Genomics Methods and products for analyzing polymers
US6891032B2 (en) 1997-08-06 2005-05-10 Ambion, Inc. Methods and compositions for stripping nucleic acids
US6632526B1 (en) 1997-10-14 2003-10-14 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
US6458583B1 (en) 1998-09-09 2002-10-01 Agilent Technologies, Inc. Method and apparatus for making nucleic acid arrays
US7026124B2 (en) 1998-09-09 2006-04-11 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
US6465183B2 (en) 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
US6461816B1 (en) 1999-07-09 2002-10-08 Agilent Technologies, Inc. Methods for controlling cross-hybridization in analysis of nucleic acid sequences
US6916661B2 (en) 1999-08-17 2005-07-12 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
US7122303B2 (en) 1999-09-17 2006-10-17 Agilent Technologies, Inc. Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same
US7052841B2 (en) 1999-11-08 2006-05-30 Agilent Technologies, Inc. Systems, tools and methods of assaying biological materials using spatially-addressable arrays
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
WO2011048222A1 (fr) * 2009-10-23 2011-04-28 Cellerix S.A. Populations cellulaires ayant une activité immunorégulatrice, procédés de préparation et utilisations associés

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
ANDREAS KURTZ ET AL: "Age related changes of the extracellular matrix and stem cell maintenance", PREVENTIVE MEDICINE, vol. 54, 20 January 2012 (2012-01-20), pages S50 - S56, XP028486146, ISSN: 0091-7435, [retrieved on 20120120], DOI: 10.1016/J.YPMED.2012.01.003 *
AREMAN EM; LOPER K, CELLULAR THERAPY: PRINCIPLES, METHODS AND REGULATIONS, 2009, pages 581 - 591
BIEBACK ET AL., TRANSFUS. MED. HEMOTHER., vol. 35, 2008, pages 286 - 294
DE LA FUENTE ET AL., EXP. CELL RES., vol. 297, 2004, pages 313 - 328
DELORME B ET AL., REGEN MED, vol. 1, 2006, pages 497 - 509
FERNANDEZ-GUTIERREZ B ET AL: "072 MESENCHYMAL STEM CELLS IN OA PATIENTS: DOWNREGULATION OF WNT SIGNALING PATHWAY AND MIR335", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 18, 1 October 2010 (2010-10-01), pages S39, XP027316628, ISSN: 1063-4584, [retrieved on 20100929] *
FLAVIO A CARRION ET AL: "Mesenchymal stem cells for the treatment of systemic lupus erythematosus: is the cure for connective tissue diseases within connective tissue?", STEM CELL RESEARCH & THERAPY, vol. 2, no. 3, 1 January 2011 (2011-01-01), pages 23, XP055083245, ISSN: 1757-6512, DOI: 10.1371/journal.pone.0004992 *
H. LIANG ET AL: "Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury", EUROPEAN HEART JOURNAL, vol. 34, no. 22, 23 May 2011 (2011-05-23), pages 1681 - 1690, XP055082889, ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehr131 *
JIN ZHANG ET AL: "Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 26, no. 8, 20 August 2011 (2011-08-20), pages 1953 - 1963, XP055083062, ISSN: 0884-0431, DOI: 10.1002/jbmr.377 *
LEMAITRE ET AL., PROC. NATL. ACAD. SCI., vol. 84, 1987, pages 648 - 652
LETSINGER ET AL., PROC. NATL. ACAD. SCI. OR.S.A., vol. 86, 1989, pages 6553 - 6556
LU ET AL., NATURE, vol. 435, 2005, pages 7043
LURIA ET AL., TRANSFUSION, vol. 11, 1971, pages 345 - 349
M TOMÉ ET AL: "miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells", CELL DEATH AND DIFFERENTIATION, vol. 18, no. 6, 17 December 2010 (2010-12-17), pages 985 - 995, XP055082824, ISSN: 1350-9047, DOI: 10.1038/cdd.2010.167 *
MINFENG SHU ET AL: "Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 19 May 2011 (2011-05-19), pages 59, XP021103684, ISSN: 1476-4598, DOI: 10.1186/1476-4598-10-59 *
NEELY ET AL., NAT. METHODS., vol. 3, no. 1, 2006, pages 41 - 6
NELSON ET AL., NAT. METHODS, vol. 1, no. 2, 2004, pages 155 - 61
PREVOSTO C ET AL: "Generation of CD4(+) or CD8(+) regulatory T cells upon mesenchymal stem cell-lymphocyte interaction", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, ROME, IT, vol. 92, no. 7, 1 July 2007 (2007-07-01), pages 881 - 888, XP002620767, ISSN: 0390-6078, DOI: 10.3324/HAEMATOL.11240 *
ROSSI, CURRENT BIOLOGY, vol. 4, 1994, pages 469 - 471
SAMBROOK ET AL.: "Molecular cloning: a Laboratory Manual", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS
STEIN ET AL., CANCER RES, vol. 48, 1988, pages 2659 - 2668
VAN DER KROL ET AL., BIOTECHNIQUES, vol. 6, 1988, pages 958 - 976
WU ET AL., RNA, vol. 13, no. 1, 2007, pages 151 - 9
ZON, PHARM. RES., vol. 5, 1988, pages 539 - 549

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170101147A (ko) * 2016-02-26 2017-09-05 에스씨엠생명과학 주식회사 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물
EP3388514A4 (fr) * 2016-02-26 2018-10-24 SCM Lifescience Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par des lymphocytes t régulateurs
KR102025417B1 (ko) * 2016-02-26 2019-09-25 에스씨엠생명과학 주식회사 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물
AU2017224499B2 (en) * 2016-02-26 2020-10-08 Scm Lifescience Co., Ltd. Pharmaceutical composition for preventing or treating regulatory T cell-mediated diseases

Also Published As

Publication number Publication date
ES2434853B1 (es) 2014-09-30
ES2434853A1 (es) 2013-12-17
WO2013186418A9 (fr) 2014-04-17

Similar Documents

Publication Publication Date Title
Guay et al. Lymphocyte-derived exosomal microRNAs promote pancreatic β cell death and may contribute to type 1 diabetes development
Djeghloul et al. Age-associated decrease of the histone methyltransferase SUV39H1 in HSC perturbs heterochromatin and B lymphoid differentiation
Kim et al. MicroRNAs are required for the feature maintenance and differentiation of brown adipocytes
Shan et al. Distinct populations of adipogenic and myogenic Myf5-lineage progenitors in white adipose tissues
Zhang et al. The microRNA-17–92 cluster enhances axonal outgrowth in embryonic cortical neurons
Chang et al. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1
CN103210085B (zh) 用于治疗或诊断骨障碍和/或心血管障碍的组合物
US20160143939A1 (en) Compositions, kits and methods for treatment of cardiovascular,immunological and inflammatory diseases
JPWO2008084319A1 (ja) 新規核酸
JPWO2008029790A1 (ja) 新規核酸
WO2015161255A1 (fr) Procédés d'augmentation ou de diminution des taux de mir124 et mir29 chez des sujets atteints de dystrophie musculaire
Zhang et al. MicroRNA let-7a ameliorates con A-induced hepatitis by inhibiting IL-6-dependent Th17 cell differentiation
US20130302293A1 (en) Compositions, cells, kits and methods for autologous stem cell therapy
Oskowitz et al. Drosha regulates hMSCs cell cycle progression through a miRNA independent mechanism
US11879137B2 (en) Treatment of type 1 diabetes and autoimmune diseases or disorders
WO2012092382A2 (fr) Rôle du miarn dans la réponse immunitaire en cellules t
JP5804459B2 (ja) 癌疾患用細胞老化促進剤
WO2013186418A1 (fr) Marqueur moléculaire de puissance thérapeutique de cellules mères mésenchymales humaines et ses utilisations
WO2008053909A1 (fr) Agent destiné à réguler la croissance et/ou la différenciation d'une cellule souche mésenchymateuse
EP2604686B1 (fr) Cellule souche/cellule précurseur à fonction élevée par introduction du gène ape1
CN112089733B (zh) 一种改造的脐带干细胞在制备抗衰老的药物组合物或者保健品中的用途
CN104774966A (zh) 肺腺癌miRNA标记物
Le et al. Platelet-derived growth factor receptor-alpha expressing cardiac progenitor cells can be derived from previously cryopreserved human heart samples
CN112280742A (zh) 干细胞制备的抗衰老的药物组合物或者保健品
JP2022543589A (ja) Ｋｌｆ誘導心筋再生

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13752910

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13752910

Country of ref document: EP

Kind code of ref document: A1